GDA, a web-based tool for Genomics and Drugs integrated analysis by Caroli, Jimmy et al.
W148–W156 Nucleic Acids Research, 2018, Vol. 46, Web Server issue Published online 25 May 2018
doi: 10.1093/nar/gky434
GDA, a web-based tool for Genomics and Drugs
integrated analysis
Jimmy Caroli1, Giovanni Sorrentino2, Mattia Forcato1, Giannino Del Sal3,4 and
Silvio Bicciato1,*
1Dept. of Life Sciences, University of Modena and Reggio Emilia, Via G. Campi, 287, 41125 Modena, Italy,
2Laboratory of Metabolic Signaling, Ecole Polytechnique Fe´de´rale de Lausanne EPFL, Lausanne, Switzerland,
3Laboratorio Nazionale CIB, Area Science Park Padriciano, Trieste, Italy and 4Dept. of Life Sciences, University of
Trieste, Trieste, Italy
Received January 30, 2018; Revised May 03, 2018; Editorial Decision May 03, 2018; Accepted May 08, 2018
ABSTRACT
Several major screenings of genetic profiling and
drug testing in cancer cell lines proved that the in-
tegration of genomic portraits and compound activ-
ities is effective in discovering new genetic mark-
ers of drug sensitivity and clinically relevant anti-
cancer compounds. Despite most genetic and drug
response data are publicly available, the availabil-
ity of user-friendly tools for their integrative analy-
sis remains limited, thus hampering an effective ex-
ploitation of this information. Here, we present GDA,
a web-based tool for Genomics and Drugs integrated
Analysis that combines drug response data for >50
800 compounds with mutations and gene expression
profiles across 73 cancer cell lines. Genomic and
pharmacological data are integrated through a mod-
ular architecture that allows users to identify com-
pounds active towards cancer cell lines bearing a
specific genomic background and, conversely, the
mutational or transcriptional status of cells respond-
ing or not-responding to a specific compound. Re-
sults are presented through intuitive graphical rep-
resentations and supplemented with information ob-
tained from public repositories. As both personalized
targeted therapies and drug-repurposing are gaining
increasing attention, GDA represents a resource to
formulate hypotheses on the interplay between ge-
nomic traits and drug response in cancer. GDA is
freely available at http://gda.unimore.it/.
INTRODUCTION
Since the pioneering NCI-60 panel (1,2), diverse cancer cell
lines have been used in large-scale screenings of combined
small-molecule sensitivity and genomic profiling to investi-
gate how genetic backgrounds and transcriptional portraits
shape cancer response to therapy and to identify disease-
specific genes associated with drug response (3–7). Histori-
cally, pharmacogenomics screenings have been largely het-
erogeneous in terms of investigated cell lines, assay tech-
nologies, number of compounds, type and quality of ge-
nomic data and methods for their computational analy-
sis. In particular, the NCI-60 study screened >50 800 com-
pounds on a panel of about 60 cell lines characterized with
genetic, transcriptional and phenotypic data (2,8–10). Dif-
ferently, the Cancer Cell Line Encyclopedia (CCLE; (4))
and the Genomics of Drug Sensitivity in Cancer (GDSC;
(3,11)) projects profiled the genome of >1000 cancer cell
lines, but probed both collections against small sets of an-
ticancer drugs (24 and 265, respectively). Finally, more re-
cent studies selected CCLE subsets for screening hundreds
of small molecules and compounds (5,6). The analysis of
this enormous and heterogeneous amount of data requires
computational methods that, through common data for-
mats, robust statistics, and user-friendly interfaces, allow the
integration of genomic profiles with drug responses across
multiple screenings.
Here, we present GDA (Genomics and Drugs integrated
Analysis), a web-based tool for the integrative analysis of
drug response data, mutations, and gene expression profiles
in a panel of 73 cancer cell lines treated with 50 816 com-
pounds. GDA builds on our previously publishedMutation
and Drug Portal (MDP; (12)) that was developed to match
response data of the NCI-60 DTP drug screening with mu-
tations from the CCLE andNCI-60 profiling. Briefly,MDP
offered the possibility to overcome the limited number of
molecules investigated in the CCLE study by correlating
CCLE genomic data to the NCI-60 DTP large panel of
drug responses. In its original version, MDP could only
be queried for discovering associations between gene mu-
tations and drug families with growth-inhibitory effects on
cancer cell lines bearing those mutations or to identify the
mutational background of cancer cell lines responsive (or
non-responsive) to a given compound. Both types of queries
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could be performed using the variant data for 1651 onco-
genes fromCCLE or the whole-exome sequencing of 15 000
human genes from the NCI-60 repository. Although MDP
proved its efficacy in retrieving both known and novel phar-
macogenomics associations between genemutations and re-
sponses of mutated cell lines towards precise compounds,
still the absence of gene expression data represented a ma-
jor limitation to identify multiple levels of interactions be-
tween drug responses and genomic determinants. To over-
come this limitation, we developed GDA, a web server that
adds the integrative analysis of transcriptional profiles and
drug response data toMDP original functionalities. Specif-
ically, starting form a list of genes, GDA can be queried to
identify drugs showing activity towards cells with a defined
transcriptional portrait. Vice versa, starting from a com-
pound, GDA retrieves gene signatures that differentiate re-
sponsive from non-responsive cell lines. These gene signa-
tures can be directly functionally annotated using Enrichr
(13), compared to results from the Library of Integrated
Network-Based Cellular Signatures (LINCS) L1000 project
(14,15), or used to identify drugs with growth-inhibitory
effects. Furthermore, to support the design of novel an-
ticancer molecules, we implemented a structural similar-
ity analysis to verify the existence of a shared, common
structure among compounds active in cells with a specific
genomic background. All analysis modules are accessible
through a user-friendly graphical interface that does not
require any programming skill and results are returned as
intuitive graphical representations and downloadable ta-
bles. In this manuscript, we summarize the modules for the
identification of drugs correlated to gene mutations (from
gene to drug) and of gene mutations associated to drug re-
sponse (from drug to gene), already implemented in MDP,
and present the major novelties introduced by GDA, i.e. the
from signature to drug and the from drug to signature mod-
ules, the structural clustering of significant drugs, and the
differential analysis of gene expression levels in cell lines re-
sponsive or non-responsive to a given compound. A step-
by-step guide to a complete analysis in GDA is reported in
the Supplementary Information.
WEBSERVER CONTENT AND ARCHITECTURE
The GDA webserver comprises drug response, exome-
sequencing, and gene expression profiling data from the
NCI-60 and the CCLE datasets, 2D compound structures
from PubChem, a modular web interface for querying data
and visualizing results, and a backend based on Python and
R for the statistical analyses.
Database content
Drug response data of 115 cancer cell lines treated with 50
816 compounds were derived from the NCI-60 GI50 file
(https://wiki.nci.nih.gov/display/NCIDTPdata/NCI-60+
Growth+Inhibition+Data; September 2014 release) and
transformed into relative sensitivities (RS) as described
in (16). Briefly, the GI50 value, i.e. the drug concentration
required for 50% growth inhibition in vitro as named by
NCI-60 DTP (https://dtp.cancer.gov/databases tools/docs/
compare/compare methodology.htm), was transformed
into relative sensitivities by mean centering, in logarithmic
scale, the GI50 of each compound in each cell line (i.e.
RS = log2GI50 – average(log2GI50)) where the average
is taken across all cell lines). Based on the RS values,
each combination of drug and cell line was classified as
responsive (or non-responsive) if the RS was lower (or
higher) than two standard deviations of the distribution
of all RS in the given cell line (16,17). Mutation calls for
the CCLE panel were retrieved from the CCLE portal
(https://portals.broadinstitute.org/ccle/data) and exome
sequencing data for the NCI-60 cell lines were obtained
from CellMiner (https://discover.nci.nih.gov/cellminer/
loadDownload.do). Raw gene expression data of CCLE
and NCI-60 cell lines were downloaded from Gene Expres-
sion Omnibus (GEO) series GSE36133 and GSE32474,
respectively. Prior to analysis, we merged the two series
in a compendium of 231 samples representing the 73
cell lines that had at least one sample in at least one
series. The compendium comprises at least four replicate
samples for >80% of the different cell lines. Expression
values were generated from intensity signals using the
multi-array average procedure (RMA) and a custom CDF
based on Entrez genes for Affymetrix HG-U133 Plus2
arrays (http://brainarray.mbni.med.umich.edu/Brainarray/
Database/CustomCDF/genomic curated CDF.asp).
Drug structures were retrieved from the PubChem FTP
site (ftp://ftp.ncbi.nlm.nih.gov/pubchem/Compound/
CURRENT-Full/SDF/) in SMILES (Simplified
Molecular-Input Line-Entry) format and matched to
NCI-60 drug names using the CID (PubChem Compound
Identification) name format. The central objects of the
database, used to link NCI-60 drug responses to CCLE and
NCI-60 genomic data, are the cancer cell lines in common
between the NCI-60 drug screening and the CCLE and
NCI-60 genomic repositories (Figure 1).
Analysis modules
GDA is composed of four main analysis modules that al-
low identifying (i) drugs active in cancer cell lines bearing
specific gene mutations (from gene to drug); (ii) gene muta-
tions characterizing cancer cell lines that are responsive to
a selected compound (from drug to gene); iii) drugs active
in cancer cell lines bearing the activation of a specific gene
signature (from signature to drug); and iv) up- and down-
regulated genes in cancer cell lines that respond to a spe-
cific compound (from drug to signature) (Figure 1). Queries
are performed through drop-down menus and either check-
boxes or radio buttons, depending on the type of input.
In the from gene to drug and from drug to gene modules,
genes and compound are selected via a drop-down menu
that auto-completes based on the gene mutations and drugs
present in the database. In the from signature to drug, gene
lists can be pasted into a dedicated input text box or up-
loaded as a text file using HUGO symbols for the gene
names.
In the from gene to drug analysis, given a set of muta-
tions, compounds are ranked based on an enrichment score
given by the fraction of cell lines bearing the set of muta-
tions that are responsive multiplied by the fraction of non-
mutated cell lines that are non-responsive (12). The statisti-
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Figure 1. Overview of GDA data analysis workflow. GDA is based on the pharmacological data obtained from the NCI-60 screening for a total of 50,816
compounds on 115 cancer cell lines and on the genomic and transcriptional profiles of the CCLE and NCI-60 studies. GDA can be interrogated through
four main modules to identify drugs active in cancer cell lines bearing specific gene mutations (from gene to drug); gene mutations characterizing cancer cell
lines that are responsive to a selected compound (from drug to gene); drugs active in cancer cell lines bearing the activation of a specific gene signature (from
signature to drug); and up- and down-regulated genes in cancer cell lines that respond to a specific compound (from drug to signature). Results from the
analyses can be fed into additional GDAmodules (as the drug clustering, the Maximum Common Structure, and the differential gene expression analyses)
or sent to external web services (as Enrichr, L1000CDS2 and PubChem) for functional annotation and comparison.
cal significance (P-value) is computed, for each drug, us-
ing a one-tailed Fisher’s exact test for the enrichment of
mutant and responsive as compared to wild-type and non-
responsive cell lines, given the number of non-responses and
responses in mutant and wild-type cells, respectively (12).
The same ranking function and statistical test is used to
identify themost enrichedmutations starting from a drug in
the from drug to genemodule. In this case, the RS values of
the queried compound are used to partition cells lines in re-
sponsive and non-responsive and then each gene mutation
in each cell line is ranked based on the enrichment score
and the statistical significance defined in the from gene to
drug module (12). Both from gene to drug and from drug to
gene queries can be run either on the CCLE genomic data,
containing variant calls for a limited set of 1651 oncogenes,
or on the NCI-60 exome sequencing data for 15 000 genes.
The from signature to drug and from drug to signature
modules exploit the transcriptional data of the gene expres-
sion compendium. In the from signature to drug, cell lines
are first split into two groups (i.e. high- and low-signature)
based on the sign of a signature score quantified as the
sum of the standardized expression values of genes com-
posing the input gene list (18). Then, similarly to the mu-
tation and drug modules, each drug is ranked according to
the score and statistical significance of the enrichment of
responses in the group of cell lines with either high or low
signature (depending if the gene signature is considered up-
or down-regulated). In the from drug to signature module,
first cell lines are split into responsive and non-responsive
based on the RS of the queried compound and then, if
each group contains at least three samples, the transcrip-
tional profiles of responsive and non-responsive cell lines
can be analyzed using either SAM (Significance Analysis
of Microarray; (19)) or a t-test to determine the list of up-
and down-regulated genes in responsive and non-responsive
cells.
From the result page of the from gene to drug, it is pos-
sible to access two additional modules, i.e. the drugs clus-
tering and, once a drug is selected, the differential expres-
sion analysis. The drug clustering (available also in the from
signature to drug result page) groups active compounds
based on the similarity of their chemical structures. Briefly,
first the SMILES structures of statistically significant com-
pounds (e.g. with enrichment score ≥ 0.3 and P-value ≤
0.05) are converted into structural coordinates (coded in the
structural data information files); then, drugs are grouped
based on their structural coordinates using a hierarchical
agglomerative clustering with Pearson correlation as dis-
tance metric and average agglomeration method (as im-
plemented in the function hclust of the R stats package).
Once clustered, a group of compounds can be analyzed to
identify a shared molecular scaffold using the Maximum
Common Structure (MCS) algorithm of the fmcs package
(https://bitbucket.org/dalke/fmcs; (20)). The differential ex-
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pression module allows comparing the gene expression lev-
els in the cancer cell lines responsive to a statistically signif-
icant drug and bearing a specific gene mutation (Group A)
against the gene expression levels of cell lines (GroupB) that
are either (i) non-responsive to the selected drug and lacking
the mutation in the selected gene; (ii) responsive to the se-
lected drug even if lacking the mutation in the selected gene
or (iii) non-responsive to the selected drug although bear-
ing the mutation in the selected gene. As in the from drug
to signature module, differential expression analysis can be
run using SAM (Significance Analysis of Microarray; (19))
or a parametric test (t-test).
Output description
The various modules generate different result pages. Specif-
ically, the from gene to drug analysis returns the list of all
drugs that are active on the analyzed cell lines bearing the
selected set of mutations and the list of drug families that
are significantly enriched, given the set of active drugs (Fig-
ure 2A). In the table of active drugs, molecules are identi-
fied in terms of compound ID (linking to PubChem), name,
drug family, mechanism of action (MoA), score and sta-
tistical significance. Results can be downloaded in tabular
form for storage and external analyses, as well as visual-
ized using different graphical representations. The plots dis-
play (i) the score andP-value of statistically significant com-
pounds; (ii) the distribution of compound scores grouped
by drug family; (iii) the distribution of relative sensitivity in
mutant/responsive and wild-type/non-responsive cell lines
and (iv) the gene expression level of the selected gene in
mutant/responsive and wild-type/non-responsive cell lines
(Figure 2B). The from signature to drug module returns the
same outputs of the from gene to drug module listing all
drugs that are active on cell lines with the up- or down-
regulation of the input gene signature. The result page of
the from drug to gene module reports the chemical struc-
ture of the input compound with the number of mutations
found statistically correlated to response and no-response;
an interactive volcano plot showing score and P-value of
gene mutations present in cancer cell lines that are respon-
sive (non-responsive) to the selected compound; the distri-
bution of mutations in cell lines, tissues, and variant types;
the list of all mutations that have been found present in can-
cer cell lines responsive (non-responsive) to the action of the
selected compound, along with their functional and struc-
tural annotations. The output page of the from drug to sig-
nature analysis provides the lists of genes over-expressed in
responsive (Group A) and non-responsive (Group B) can-
cer cell lines. These lists can be functionally annotated us-
ing Enrichr (13), compared to results of the LINCS project
through the LINCS L1000 characteristic direction signa-
tures search engine (L1000CDS2; (14)), or directly used to
generate gene signatures for the from signature to drugmod-
ule ofGDA (Figure 3A). Finally, the output page of the drug
clustering (accessible from the from gene to drug and from
signature to drugmodules) provides an interactive clustering
tree of all significant drugs grouped by structural similarity
(Figure 3B). Once selected, each node of the tree returns a
list of molecules that can be further used in the Maximum
Common Structure analysis to retrieve a common scaffold
shared by all compounds belonging to the group.
Web implementation
GDA is based on the lightweight and flexible Twig tem-
plate engine for PHP (https://twig.symfony.com/) for a fast
crosstalk between web pages and analysis modules. The web
interface is structuredwith PHP 5.0,HTML5.0, and a com-
pletely customized CSS for buttons and animations. Sta-
tistical analyses are performed using Python 2.7 cgi scripts
that have been optimized for fast fetching and data delivery
and are structured to interact with R (version 3.1.2). For
the graphical representations of results, we used the jQuery
JavaScript library 2.1.1 (https://jquery.com/), based on the
structure of the latest Google APIs release (2016), and the
Plotly JavaScript library 1.35.2 (https://plot.ly/javascript/).
The connections to Enrichr and L1000CDS2 have been
coded using the javascript APIs provided by Enrichr (http://
amp.pharm.mssm.edu/Enrichr/help#api) and a Python 2.7
cgi script (http://amp.pharm.mssm.edu/L1000CDS2/help/
#python), respectively. GDA is hosted on a Linux server
with 512 GB RAM and 64 processors, can work on any re-
cently updated browser, and is designed to record all per-
formed analyses for a fast fetching of results (i.e. results are
immediately loaded if the query of interest has been submit-
ted before).
CASE STUDY RESULTS
The tutorial, available as Supplementary Information and
on theGDAwebsite, provides representative case studies for
each of the four analysis modules, including sample inputs
and working examples. Here, we will briefly present how
GDA can integrate drug responses, mutations, and gene
expression profiles to formulate hypotheses on the mech-
anisms connected to drug resistance or to elucidate the in-
terplay between the transcriptional activation of signaling
pathways and drug response.
Identification of no-response mechanisms to BRAF inhibitors
Cancers bearing somatic BRAF mutations, and in partic-
ular the V600E mutation within the kinase domain, are
treated with BRAF inhibitors like Dabrafenib (21) and
Vemurafenib (22), but although these therapies improved
overall and disease-free survival, nonetheless almost 20%
of the patients do not respond to the treatment. To dis-
cover putative mechanisms of drug resistance in cancers
with BRAF mutations, we first identified drugs active in
cancer cell lines with BRAF missense mutations using the
from gene to drugmodule. The analysis returned, among the
most active compounds, the Imatinib analogs Dabrafenib
(21), Vemurafenib (22), and Selumetinib (Figure 2A). Then,
to search for genes likely interfering with the anticancer ac-
tion of e.g. Vemurafenib, we investigated (using SAM dif-
ferential expression analysis and responsive cells with the
mutation as control group; Group A) the gene expression
profiles of cell lines that, although bearing BRAF mis-
sense mutations, do not respond to the treatment with Ve-
murafenib (Group B). The comparison indicated that cells
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Figure 2. Result pages of the from gene to drug and from signature to drugmodules. (A) The result pages of the from gene to drug and from signature to drug
analyses list of all drugs that are active on cell lines bearing the selected genomic background. In the table, drugs are identified in terms of compound ID
(linking to the PubChem), name, drug family, mechanism of action (MoA), score and statistical significance. (B) Results can be visualized in terms of (from
top left to bottom right): score and P-value of statistically significant compounds; distribution of compound scores grouped by drug family; distribution
of relative sensitivity in mutant/responsive and wild-type/non-responsive cell lines; gene expression level of the selected gene in mutant/responsive and
wild-type/non-responsive cell lines.
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Figure 3. Result pages of the from drug to signature and drug clustering modules. (A) The output page of the from drug to signature analysis provides the
lists of genes over-expressed in responsive (Group A) and non-responsive (Group B) cancer cell lines. These lists can be linked to external web services or
directly used to generate gene signatures for the from signature to drug module of GDA. (B) The output page of the drug clustering returns an interactive
clustering tree of all significant drugs grouped by structural similarity.
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non-responsive to Vemurafenib over-express (at FDR ≤
0.05) a total of 1043 genes and that those with a fold change
≥2 (316 genes) are functionally enriched in theKEGGpath-
way of insulin resistance, ultimately mediated by activation
of the PI3K/Akt pathway. Intriguingly, this result supports
previous evidences of a mechanistic link between insulin,
the PI3K/Akt pathway, and attenuated therapeutic efficacy
of BRAF inhibitors and suggests that the defective response
to Vemurafenib might be overcome by the concomitant use
of PI3K inhibitors (23).
Interplay between transcriptional activation of signaling
pathways and drug sensitivity
The phosphatase and tensin homolog (PTEN) protein is
a phosphatase that inhibits the phosphoinositol-3-kinase
(PI3K)/AKT signaling pathway and suppresses cell sur-
vival as well as cell proliferation. Loss of function muta-
tions in the PTEN gene have been associated with a wide
range of human tumors,making PTEN the secondmost fre-
quently mutated gene in human cancers after TP53. Tran-
scriptional signatures of PTEN have been used to inves-
tigate the molecular consequences of PTEN loss in can-
cer. We took advantage of a loss-of-function PTEN sig-
nature (PTEN DN.V1 UP gene set of the Molecular Sig-
natures Database; http://software.broadinstitute.org/gsea/
msigdb/index.jsp) obtained from isogenic tumor cell line
pairs in which PTEN was inactivated through RNA inter-
ference (24) to identify drugs with selective cytotoxicity for
cancer cells showing PTEN inactivation. To this aim, we
used the from signature to drug analysis and, among the
compounds predicted to be active on all tissues, we found
several mitochondrial inhibitors (as Leucinostatin-A, Os-
samycin, Cytovaricin, Oligomycin-A, Oligomycin-B, and
Oligomycin-C; Figure 4A) that have been recently demon-
strated to be selective cytotoxic drugs for PTEN-null can-
cer cells (25). Conversely, we used the from drug to signature
module to identify signaling pathways active in cells respon-
sive to mitochondrial inhibitors. The functional enrichment
of over-expressed genes in cells responsive to Oligomycins
or Trichopolyn-B (Up in Group A at FDR< 0.05) indicated
that sensitivity to mitochondrial inhibitors is accompanied
by the activation of oxidative phosphorylation, respiratory
electron transport chain, and ATP synthesis pathways (Fig-
ure 4B), thus suggesting a possible mechanism of action of
these compounds in cancer cells (25).
COMPARISON TO OTHER SIMILAR TOOLS
GDA can be compared to some other tools for the inte-
grative analysis of pharmacological and genomic data in
cancer cell lines, as for instance CellMiner and CellMiner
Cross Database (CellMinerCDB) (8,9); CancerResource
(26); CancerDR (27); the Sanger Genomics of Drug Sen-
sitivity in Cancer (GDSC) data portal (11) and the Can-
cer Therapeutics Response Portal (5–7). However, among
these tools, only CellMinerCDB and CancerResource, as
GDA, integrate drug activity and molecular data obtained
from both CCLE and NCI-60 DTP consortia thus allow-
ing to cross-interrogate, e.g. the extensive pharmacologi-
cal collection of the NCI-60 on the genomic data of the
CCLE profiling. Although lacking the data of the Sanger
GDSC project, included in both CellMinerCDB and Can-
cerResource, GDA still present some advantages over both
tools in terms of analysis options, usage simplicity, and in-
teractive visualization of results. CellMinerCDB (https://
discover.nci.nih.gov/cellminercdb/) is still in a developmen-
tal phase and the analyses are limited to the visualization of
univariate associations and regressions between predefined
entities (e.g. one gene and one compound). CancerResource
(http://data-analysis.charite.de/care/index.php) contains no
module for a direct integrative analysis of genomic features
and pharmacological data. Instead, mutations and gene sig-
natures are used to identify a set of cell lines that share sim-
ilar genomic traits and the most effective drugs are then
listed for any single cell lines, thus missing the direct asso-
ciation between a specific genomic background and the re-
sponse to a drug, irrespective of the tissue type. Differently
from similar tools, GDA (i) directly integrates genomic and
pharmacological data from the two largest screenings of
combined small-molecule sensitivity and genomic profiling
in cancer cell lines; (ii) allows both the identification of com-
pounds active towards cancer cell lines with given muta-
tional or transcriptional traits and the mutational or tran-
scriptional portraits of cells responsive or non-responsive
to a specific compound; (iii) has a completely interlaced
modular architecture that allows feeding results from one
analysis as input to other modules without any external,
manual rearrangement of the data and (iv) returns results
through a set of intuitive graphical representations and tab-
ular formats, supplementedwith direct link to public reposi-
tories. A unique feature of GDA is the gene expression com-
pendium. Given the high concordance between CCLE and
NCI-60 gene expression measurements (28,29), we gener-
ated gene expression data merging the two transcriptional
studies, thus obtaining a number of replicates per single cell
line that allows statistically robust differential analyses be-
tween any subgroup defined, e.g. on drug response or signa-
ture activation. As compared to MDP (12), GDA presents
several major enhancements and updates including: (i) the
addition of the gene expression data and of all related mod-
ules; (ii) the drug clustering andMaximumCommon Struc-
ture analyses to test the existence of a shared, common
structure among active compounds and (iii) a re-designed
interface comprising entirely new graphical representation
and annotation of results.
CONCLUSIONS AND OUTLOOK
Large-scale screenings of genomic profiles and pharmaco-
logical responses provide a unique resource to formulate hy-
potheses on the interplay between genomic traits and drug
sensitivity or resistance in cancer. However, to be exten-
sively exploited by the scientific community, these data re-
quire computational tools that combine robust integrative
analyses with easy-to-use, user-friendly interfaces. GDA is
a webserver designed to facilitate the integrative analysis
of genomic and drug response data available from two ma-
jor cancer cell line screens (i.e. the NCI-60 and the Cancer
Cell Line Encyclopedia) for the systematic identification of
new biomarkers of drug sensitivity and the selection of pu-
tative therapeutic options for patients that, based on their
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Figure 4. Transcriptional activation of signaling pathways and drug sensitivity. (A) The from signature to drug analysis indicates that cancer cells showing
PTEN inactivation are responsive to mitochondrial inhibitors. (B) Genes identified by the from drug to signaturemodule as up-regulated in cells responsive
to mitochondrial inhibitors (as e.g. Oligomycin-A at FDR < 0.05) are functionally enriched in the activation of oxidative phosphorylation, respiratory
electron transport chain and ATP synthesis pathways.
genomic background, fail to respond to standard therapies.
A key feature of the webserver is its user-friendly web in-
terface that does not require any bioinformatics expertise
nor manual formatting of the data to input the various, in-
tertwined analysis modules. Given some reported discrep-
ancies between drug sensitivity measurements in the vari-
ous studies (28,29), the current version of GDA incorpo-
rates only the pharmacological data of the NCI-60 project.
Nonetheless, its modular architecture can, in principle, host
genomic and pharmacological information from any other
screening as, for instance, epigenomic profiles and sensitiv-
ities to specific drugs or combinations of drugs of patient-
derived models (as cell cultures, xenografts and organoids)
directly interrogated as in vitro proxy of human tumors.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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